Though sales for Pfizer's (NYSE:PFE) drug Lipitor -- the highest selling drug of all time -- have been down dramatically now that the drug has gone off patent and faces generic competition, this was actually a strong year for Pfizer. It sold its infant nutrition division and is spinning out its animal health division to focus entirely on pharmaceuticals.

In the following video, health care analysts Max Macaluso and Brenton Flynn offer an overview of Pfizer and discuss what investors can expect from the company's drug portfolio and pipeline.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.